AMRN

TentativeAI Memo

Amarin

As of 2026-10-06/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-06 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Action

—

Confidence

medium

Horizon

6‑12m

Key catalyst

Additional international access and launches • 2027-06-30

Base target: $13 / p=50% prob

Biggest risk

Q2 revenue declined 42% year over year and the company still reported an operating loss. Early international volume gains may not offset U.S. and European revenue pressure quickly enough [#SEC-8K-2026-07-29].

Invalidation

Break below $8 or thesis failure.

What would change my mind?

Partner-network demand growth, a completed cost-reduction initiative and $314.6 million of June 2026 cash could support value if they translate into sustained cash generation and Amarin-level revenue [#SEC-8K-2026-07-29].

Research note

Recommendation

—

Confidence

medium

As of

2026-10-06

Base target

$13

p=50%

Bull target

$16

p=25%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

2026 cash-flow and U.S.
sales validation
Recordati partnership monetization

BearKey bullets

Failure to sustain lower operating expenses or positive cash flow would weaken the central thesis.
Generic icosapent competitors provide product-market context, but their diversified businesses do not supply reliable company-level valuation comparables; analyst coverage and revisions are not established.
Q2 2026 net revenue fell 42% year over year to $42.2 million even as reported in-market partner demand grew [#SEC-8K-2026-07-29].

WatchKey bullets

Additional international access and launches

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $13 (p=50%)

Target spread vs base: +23% / -38%

Scenario probabilities

Bull Target: $16 (p=25%)Base Target: $13 (p=50%)Bear Target: $8 (p=25%)

Commentary

Company evidence is constructive on partner demand, costs and cash, but negative reported revenue growth tempers it. Recent coverage is sparse; the packet documents no post-print analyst target revisions or dependable social, options, short-interest or employee measures. Zero-valued sentiment fields denote unavailable data, not neutral readings. No verified immediate post-release price reaction is available. The positive deterministic prior does not overcome limited forward visibility or the lack of clean valuation peers.

As of 2026-10-06 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

2026 cash-flow and U.S. sales validation
Recordati partnership monetization

Scenarios

Bull Target (Scenario probability)

$16 / p=25% prob

Base Target (Scenario probability)

$13 / p=50% prob

Bear Target (Scenario probability)

$8 / p=25% prob

Analysis 2026-10-06 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2027-06-30
Additional international access and launches
Recordati-led European reimbursement and adoption remain early; Amarin also identified Singapore and South Korea as progressing toward commercialization. Documented launches or access gains could test whether partner-network demand growth converts into Amarin revenue. The date is a monitoring horizon, not company guidance [#SEC-8K-2026-07-29]. Company results
Prob 55.00% • Move 9.00% • Priced-in 40.00%

Short-term Catalysts

Next few weeks

2026 cash-flow and U.S. sales validation
2026-12-31
Amarin expects positive cash-flow generation in 2026 and broadly consistent U.S. volumes. Delivery would support its lower-cost model, but Q2 revenue fell 42% year over year despite lower expenses. The next results are a test, not a confirmed turnaround [#8-K-2026-07-29] [#SEC-8K-2026-07-29]. Company results
Prob 55% • Move 8% • Priced-in 45%

Long-term Catalysts

Months to a year

Recordati partnership monetization
2027-12-31
The license and supply agreement covers 59 countries focused on Europe. Q2 in-market demand rose 69% year over year in Europe, but sustained reimbursement, adoption and supply economics—not volume alone—must establish durable value for Amarin [#SEC-8K-2026-07-29]. Company results
Prob 55% • Move 12% • Priced-in 45%

Risks

Failure to sustain lower operating expenses or positive cash flow would weaken the central thesis.
Generic icosapent competitors provide product-market context, but their diversified businesses do not supply reliable company-level valuation comparables; analyst coverage and revisions are not established.
Q2 2026 net revenue fell 42% year over year to $42.2 million even as reported in-market partner demand grew [#SEC-8K-2026-07-29].
Reimbursement, launches and partner sell-through may take longer than expected to produce durable revenue for Amarin.

Peers

Symbol	Summary
RDY	Dr. Reddy's documented a U.S. icosapent ethyl launch and subsequent pricing pressure, making it a relevant historical product-level competitor. Its diversified scale prevents a clean company valuation comparison, and the cited filing does not establish its current product sales. Dr. Reddy's filing

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-06

Loading AI feed…

Symbol

Summary

RDY

Dr. Reddy's documented a U.S. icosapent ethyl launch and subsequent pricing pressure, making it a relevant historical product-level competitor. Its diversified scale prevents a clean company valuation comparison, and the cited filing does not establish its current product sales. Dr. Reddy's filing